Acorda Therapeutics, Inc. is a commercial-stage biopharmaceutical company that engages in identifying, developing and bringing to market therapies for multiple sclerosis (MS), spinal cord injury and other central nervous system disorders. Acorda’s products include: Ampyra (dalfampridine), a potassium channel blocker for improving walking in patients with MS; and Zanaflex capsules and tablets (tizanidine hydrochloride), a short-acting drug for managing spasticity. For more information, visit the company’s website at www.acorda.com.